Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.40 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD5 | P21918 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25796673 | 0.88 | F10 (0.41) | F10PARP1PARP2MAOAMAOB | |
| SCHEMBL22012060 | 0.84 | CA2 (0.43) | F10PARP1PARP2WDR91MAOA | |
| SCHEMBL31054271 | 0.83 | CA2 (0.42) | F10PARP1PARP2WDR91MAOA | |
| SCHEMBL30244447 | 0.82 | PARP1 (0.38) | F10PARP1PARP2WDR91MAOA | |
| SCHEMBL3652903 | 0.78 | HDAC6 (0.40) | F10MAOBALDH1A1 | |
| SCHEMBL10513565 | 0.75 | PARP1 (0.43) | F10PARP1PARP2WDR91MAOA | |
| SCHEMBL22012058 | 0.74 | DRD2 (0.36) | F10PARP1PARP2WDR91DRD2 | |
| SCHEMBL3010467 | 0.74 | ESR2 (0.50) | KDM4EMAPTADORA1 | |
| SCHEMBL17850513 | 0.73 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL8054291 | 0.73 | MAOA (0.44) | PARP1PARP2WDR91MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | F10 3512/4885PARP1 2052/4885PARP2 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.